Skip to content
Triflupromazine
Vesprin (triflupromazine) is a small molecule pharmaceutical. Triflupromazine was first approved as Vesprin on 1982-01-01. It is used to treat hiccup, nausea, pain, psychotic disorders, and vomiting in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
mental disordersD001523
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triflupromazine
Tradename
Company
Number
Date
Products
VESPRINBristol Myers SquibbN-011491 DISCN1982-01-01
1 products
Hide discontinued
Triflupromazine hydrochloride
Tradename
Company
Number
Date
Products
VESPRINBristol Myers SquibbN-011325 DISCN1982-01-01
3 products
VESPRINBristol Myers SquibbN-011123 DISCN1982-01-01
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiccup—D006606R06.6
nauseaHP_0002018D009325R11.0
painEFO_0003843D010146R52
psychotic disorders—D011618F20.81
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AA: Phenothiazines with aliphatic side-chain, antipsychotics
— N05AA05: Triflupromazine
HCPCS
Code
Description
J3400
Injection, triflupromazine hcl, up to 20 mg
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pure red-cell aplasiaD012010HP_001241011———1
Diamond-blackfan anemiaD029503D61.0111———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRIFLUPROMAZINE
INNtriflupromazine
Description
Triflupromazine is a member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position. It has a role as a dopaminergic antagonist, an antiemetic, a first generation antipsychotic and an anticoronaviral agent. It is a tertiary amine, a member of phenothiazines and an organofluorine compound. It derives from a hydride of a 10H-phenothiazine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21
Identifiers
PDB—
CAS-ID146-54-3
RxCUI10805
ChEMBL IDCHEMBL570
ChEBI ID9711
PubChem CID5568
DrugBankDB00508
UNII IDRO16TQF95Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 293 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
552 adverse events reported
View more details